Genome Editing in Human Pluripotent Stem Cells: Approaches, Pitfalls, and Solutions

William T. Hendriks,[1,2] Curtis R. Warren,[3] and Chad A. Cowan[3,4,*]
[1]The Collaborative Center for X-Linked Dystonia Parkinsonism, Department of Neurology, Massachusetts General Hospital, Charlestown, MA 02129, USA
[2]Harvard Brain Science Initiative, Harvard Medical School, Boston, MA 02114, USA
[3]Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA
[4]Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
*Correspondence: chad_cowan@harvard.edu
http://dx.doi.org/10.1016/j.stem.2015.12.002

Human pluripotent stem cells (hPSCs) with knockout or mutant alleles can be generated using custom-engineered nucleases. Transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nucleases are the most commonly employed technologies for editing hPSC genomes. In this Protocol Review, we provide a brief overview of custom-engineered nucleases in the context of gene editing in hPSCs with a focus on the application of TALENs and CRISPR/Cas9. We will highlight the advantages and disadvantages of each method and discuss theoretical and technical considerations for experimental design.

Introduction

The isolation of human embryonic stem cells (hESCs) and the discovery of human induced pluripotent stem cell (hiPSC) reprogramming have sparked a renaissance in stem cell biology, in vitro disease modeling, and drug discovery (Grskovic et al., 2011; Takahashi et al., 2007; Thomson et al., 1998). In general, hPSC-based disease models are well-suited to study genetic variation (Karagiannis and Yamanaka, 2014). Studies commonly compare patient-derived hiPSCs, e.g., with a disease-causing genetic mutation, and (age-matched) control subject-derived hiPSCs, typically differentiated to the disease-affected cell type, e.g., neurons or hepatocytes (Ding et al., 2013a; Sterneckert et al., 2014). A major caveat of this disease-modeling strategy is the variability of differentiation propensities and phenotypic characteristics, even in hPSCs derived from the same donor (Bock et al., 2011; Boulting et al., 2011). Still, even if the cellular phenotype of a given mutation is strong and highly penetrant, it may be lost due to confounding effects of differences in genetic background of unrelated hPSC lines (Merkle and Eggan, 2013; Sandoe and Eggan, 2013). A very powerful approach to overcome this hurdle is to use custom-engineered endonucleases that enable precise and programmable modification of endogenous hPSC genomic sequences (Kim and Kim, 2014). This genome-engineering strategy will prove invaluable for studying human biology and disease (Merkle and Eggan, 2013; Sterneckert et al., 2014).

Upon delivery in the cell, custom-engineered nucleases introduce site-specific double-strand breaks (DSBs) in the DNA that are repaired either through error-prone non-homologous end-joining (NHEJ) or precise homology-directed repair (HDR) (reviewed in Heyer et al., 2010; Jasin and Rothstein, 2013). DSB repair through NHEJ will typically result in small insertions and/or deletions (indels) in the target locus. These indels cause frameshift mutations, resulting in functional knockout of protein-coding genes (Ding et al., 2013a). Larger deletions can be introduced by creating two DSBs simultaneously to knock out genes, regulatory regions, or non-coding genetic loci (Canver et al., 2014). Dual DSBs will be repaired through NHEJ, deleting the complete intervening sequence (Mandal et al., 2014; Zhang et al., 2015). Precise genetic modifications such as nucleotide substitutions or deletions are achieved by co-delivery of an exogenous DNA donor template with engineered nucleases for integration through HR (Byrne et al., 2015; Hockemeyer et al., 2011).

Most engineered endonucleases comprise a customizable, sequence-specific DNA-binding domain fused to a (non-specific) DNA endonuclease domain. Although naturally occurring homing endonucleases or meganucleases have been successfully used for genome engineering (Silva et al., 2011), their application in genome editing of hPSCs has been very limited. The first custom-engineered, site-specific endonucleases successfully used for genome editing in hPSCs were zinc-finger nucleases (ZFNs) (Hockemeyer et al., 2009; Zou et al., 2009). ZFNs are fusion proteins composed of several tandem zinc-finger DNA-binding domains coupled to the FokI endonuclease catalytic domain. The DNA-binding domain of ZFNs consists of three to six zinc-finger DNA-binding domains (ZFDBD) assembled in an array. This arrayed construction of the ZFN allows for specific targeting of genetic loci, as each ZFDBD binds to a specific nucleotide triplet. FokI endonuclease is only active when homo-dimerized, further complicating ZFN construction (Bibikova et al., 2003; Urnov et al., 2005). ZFNs are relatively difficult to engineer, and their design and construction in the laboratory remain technically challenging.

An alternative custom-engineered endonuclease is the transcription activation-like effector nuclease derived from the plant pathogen *Xanthomonas* (TALEN) (Boch et al., 2009). Like ZFNs, TALENs consist of a customized TALE DNA-binding domain fused to a non-specific FokI nuclease domain. The TALE DNA-binding domain comprises arrays of 33–35 amino acids, where the amino acids in positions 12 and 13 of each array determine nucleotide binding specificity. TALEN-mediated genome editing

Figure 1. Human Pluripotent Stem Cell Gene-Editing Workflow
(1) In silico design of the TALE array or CRISPR guide RNA. (2) Cloning and construction of nuclease and guide RNA vectors, either as DNA, mRNA, or protein (3) for transfection or transduction of single-cell hPSCs is shown. (4) After transfection or transduction, gene-targeted cells can either be selected with FACS if the transfected vectors contain a fluorescent reporter or antibiotics if there is a selection marker present in the nuclease vector. (5) One to two weeks after enrichment of targeted cells, hPSC colonies (6) are picked and expanded for genomic DNA analysis and for targeted clone recovery and expansion if genome editing was successful.

in hPSCs has been used for generation of hPSC gene reporter lines, biallelic knock out of genes, and repair and introduction of point mutations (Ding et al., 2013a; Luo et al., 2014). As with the design of ZFNs, each DNA target sequence requires re-engineering of the TALEN DNA-binding domain. Recently, an increasingly popular RNA-guided endonuclease has been developed for genome editing in eukaryotes (Cong et al., 2013; Mali et al., 2013). First derived from *Streptococcus pyogenes* (SpCas9; referred to in this review as Cas9 unless otherwise noted), the Cas9 system consists of the Cas9 nuclease and short non-coding CRISPR RNA sequences referred to as single-guide RNAs (sgRNAs). These sgRNAs contain a customizable 20-nucleotide sequence that guides a co-expressed Cas9 nuclease to the sgRNA target sequence for creation of a site-specific DSB (Jinek et al., 2012).

In this protocol review, we will discuss TALEN- and CRISPR/Cas9-mediated genome-editing protocols for genome engineering in hPSCs that follow a general workflow, shown in Figure 1, and highlight problems, pitfalls, and solutions associated with each. Many of the gene-editing approaches described in this protocol review have been first validated and established in other cell types, but wherever possible, we reference their application in hPSCs.

DNA-Binding Domain, Nuclease, and Template Design
When choosing the most-suitable custom-engineered endonuclease for any given hPSC gene-targeting experiment, target site accessibility (chromatin state or methylation state) and the type of desired genetic modification must be considered. Target site binding is influenced by methylation state and is an important consideration when using TALENs because conventional TALE DNA-binding domains cannot bind and cleave targets that contain methylated cytosines, usually found within CpG

islands (Bultmann et al., 2012; Kim et al., 2013). The TALE DNA-binding affinity for its cognate DNA sequence also determines the TALEN activity. Low binding affinity results in reduced TALEN activity, and a very strong affinity reduces TALEN specificity (Guilinger et al., 2014a; Jankele and Svoboda, 2014; Meckler et al., 2013). Hyper-methylated DNA sequences may be more efficiently targeted using a CRISPR/Cas9 approach as the CRISPR guide RNA is able to bind methylated DNA (Hsu et al., 2013), but it has been suggested that CRISPR guide RNA activity is partly dependent on DNaseI hypersensitivity of the locus targeted. On the other hand, TALEN DNA-binding domains have less stringent design rules and in general are less mismatch tolerant than CRISPR/Cas9 (Hockemeyer et al., 2011; Miller et al., 2011, 2015). Whereas CRISPR/Cas9 target sites are limited to loci harboring a protospacer-adjacent motif (PAM), TALEN DNA-binding domains can be designed to target any sequence, offering substantially higher targeting densities compared to CRISPR guide RNAs (Miller et al., 2015; Reyon et al., 2012; Tsai et al., 2014). It has been estimated that there is a dimeric target site per 3 bp of random DNA sequence for TALENs based on the requirement for a 5′ T and the range of compatible spacing. The targeting range of TALENs is essentially unrestricted given the flexibility of these parameters (S. Tsai, personal communication; Reyon et al., 2012).

Both TALEN and CRISPR/Cas9 genome-editing methods have been used to target a wide variety of genomic loci for the creation of NHEJ-mediated gene knockout hPSC lines (Ding et al., 2013a; Frank et al., 2013; Li et al., 2013). CRISPR/Cas9 is generally more efficient than TALENs for NHEJ-mediated knockout of target genes (Ding et al., 2013b). The efficiency of HDR-mediated gene editing in hPSCs is comparable between CRISPR/Cas9 and TALEN (Yang et al., 2013), and both gene-editing approaches have been used to successfully generate hPSC

Table 1. Online Resources for In Silico CRISPR/Cas9 and TALEN Design

Website[a]	Application	Reference
http://crispr.mit.edu/	sgRNA/CRISPR design and off-target prediction	Hsu et al., 2013
https://tale-nt.cac.cornell.edu/	TALE design and off-target prediction	Doyle et al., 2012
http://zifit.partners.org/ZiFiT/	ZFN, TALEN, and sgRNA/CRISPR design	Sander et al., 2010
http://www.e-talen.org/E-TALEN/	TALEN design	Heigwer et al., 2013
http://www.e-crisp.org/E-CRISP/	sgRNA/CRISPR design	Heigwer et al., 2014
https://chopchop.rc.fas.harvard.edu/	TALEN and sgRNA/CRISPR design and off-target prediction	Montague et al., 2014
http://www.rgenome.net/	sgRNA/CRISPR design and off-target prediction	Bae et al., 2014
		Bae et al., 2014
http://crispr.cos.uni-heidelberg.de/	sgRNA/CRISPR design and off-target prediction	Stemmer et al., 2015
https://crispr.bme.gatech.edu/	sgRNA/CRISPR off-target prediction	Cradick et al., 2014
http://bao.rice.edu/Research/BioinformaticTools/prognos.html	ZFN and TALEN off-target prediction	Fine et al., 2014
http://watcut.uwaterloo.ca/template.php	Design of silent mutations to introduce or remove restriction sites to aid hPSC clonal analysis	NA
http://tide.nki.nl/	CRISPR/Cas9 genome-editing assessment tool	Brinkman et al., 2014[,b]

[a]Most of these resources are for the design of TALE DNA-binding arrays and sgRNA sequences as well as for the design of restriction sites in ssODNs or plasmid DNA templates.
[b]This online tool quantifies indels after CRISPR/Cas9-mediated gene targeting but cannot be used to determine efficiency of indel generation after TALEN-mediated gene targeting.

gene knockin lines (Byrne et al., 2015; Chen et al., 2014; Ding et al., 2013a; Hockemeyer et al., 2011; Hou et al., 2013; Osborn et al., 2013). For both CRISPR gRNA and TALEN DNA-binding array design, online design tools are available (Table 1).

Precise editing of point mutations or SNPs, generation of gene reporters, and precise gene deletions or insertions are HDR dependent and require an exogenous DNA template (Choulika et al., 1995). The two most-common DNA templates for HDR-mediated gene editing are single-stranded oligodeoxynucleotides (ssODNs) and plasmid DNA templates. ssODNs are most often used for introduction or repair of point mutations, whereas plasmid DNA templates are primarily used for larger gene insertions. Whereas the generation of targeting plasmids may require substantial cloning and inclusion of homology arms on 5′ and 3′ ends that ideally measure more than 400 base pairs (Hendel et al., 2014), ssODNs are typically 100–200 nucleotides long with at least 40 base pairs of homology on either side (Byrne et al., 2015; Ran et al., 2013a) and readily obtained from commercial vendors.

Design of DNA-Binding Domains—TALENs
The DNA-binding domain of TALENs can be engineered to target any DNA sequence. The TALE DNA-binding domain comprises 33–35 amino acid repeats, of which the amino acids in positions 12 and 13 in each repeat recognize a single DNA base. These two amino acids constitute the variable di-residues (RVDs). There are four canonical RVDs, NN, NI, HD, and NG, that recognize and bind guanine, adenine, cytosine, and thymine, respectively (Boch et al., 2009; Moscou and Bogdanove, 2009). TALE DNA-binding domains that target a DNA sequence containing one or more 5-methylated cytosines (5mCs), often found in CpG islands in promoter regions and proximal (5′) exons, bind their target DNA less efficiently (Bultmann et al., 2012; Reyon et al., 2012). This 5mC sensitivity can be overcome by using the demethylating agent 5-aza-dC during cell culture, though

this compound has pleiotropic effects and can result in substantial cytotoxicity (Palii et al., 2008). To avoid the use of potentially harmful demethylating compounds, Valton et al. (2012) studied 5mC binding of the alternative cytosine-binding RVD N* (Boch et al., 2009) and found a 2- to 17-fold increase in 5mC binding compared to the canonical cytosine-binding RVD HD (Valton et al., 2012). CRISPR/Cas9, on the other hand, does bind methylated sequences and is more efficient than TALEN in generating DSBs at methylated target sites (Hsu et al., 2013; Miller et al., 2011). The TALE DNA-binding array allows for more DNA sequence targeting flexibility than CRISPR gRNAs, because the only requirement is a thymine (T) immediately upstream of the DNA-binding domain (Boch et al., 2009; Moscou and Bogdanove, 2009). Recent re-engineering of synthetic RVDs has allowed for any 5′ nucleotide recognition by the N-terminal TALE domain (Lamb et al., 2013), further increasing the targeting flexibility of TALENs.

Generating a TALE DNA-binding domain is relatively straightforward, but each DNA target sequence requires re-engineering of the TALE array. In general, it is recommended to design a pair of TALENs that, including the spacer region, spans about 45–60 nucleotides (Figure 2A). Although, theoretically, this strategy would avoid off-target sites with homologous sequences as the target sequence is longer, hence more specific, TALEN off-target activity has been reported (Guilinger et al., 2014a). If the goal is to knock out a gene, ideally, the first exon should be targeted and sites that reside in the 3′ end of the coding sequence should be excluded. It is also recommended choosing a target site that resides in a common exon, in case a single gene is expressed as multiple splice variants (Kim et al., 2013). Modular multimer TALE DNA-binding arrays can be built from RVD monomers using a hierarchical or Golden Gate cloning method (Cermak et al., 2011; Engler et al., 2009; Zhang et al., 2011). A less labor-intensive and time-consuming method to assemble TALE

Figure 2. Custom-Engineered Nucleases TALEN and CRISPR/Cas9
(A) Schematic showing TALE DNA-binding array in this example comprising 15 RVDs, each binding their cognate nucleotide in the target sequence. The TALE-binding arrays each are fused to a FokI monomer. In order for FokI dimerization and DSB to occur, there needs to be a DNA spacing sequence of 15–18 nucleotides between the 5′ and 3′ TALE-binding array. The four canonical TALE RVDs are shown as well.
(B) The CRISPR/Cas9 system consists of a guide RNA that contains a 20-nucleotide-long target DNA-matching sequence immediately upstream of a protospacer adjacent motif (PAM) that for *S. pyogenes* Cas9 is NGG. Without this PAM site, the Cas9 nuclease is unable to form a complex with the guide RNA and introduce a double-stranded break.
(C) So-called Cas9 nickase (Cas9D10A) is an engineered wild-type Cas9 that creates a DNA nick instead of a DSB. Co-expression of two sgRNAs in each other's vicinity with Cas9 nickase will create DNA nicks, essentially forming a DSB. The dual nickase approach as shown in this schematic has been shown to increase specificity of gene editing (see text for details). Different Cas9 orthologs, each with their own PAM requirements, have been used for gene editing.

DNA-binding arrays is the fast ligation-based automatable solid-phase high-throughput (FLASH) system, although this method does rely on a pre-existing library of plasmids containing one to four TAL effector repeats consisting of all possible combinations of the canonical RVDs (Reyon et al., 2012). A ligation-independent cloning method has also been described to generate TALENs in a high-throughput manner (Schmid-Burgk et al., 2013). The advantage of these methods is that they are relatively fast and provide flexibility in the length of the TALE DNA-binding arrays. Although more costly, gene synthesis represents an easy way to generate codon-optimized TALENs, as has been shown for their use in hPSCs (Yang et al., 2013). Our and other labs have built libraries of plasmids containing multimer TALE DNA-binding modules that can either be easily digested and sequentially ligated into a TALEN backbone (Ding et al., 2013a) or assembled in a one-step Golden Gate cloning reaction (Kim et al., 2013). The advantage of these latter libraries is that any laboratory with basic molecular biology capabilities can cost-effectively build TALENs for genome-editing purposes.

Design of DNA-Binding Domains—CRISPR gRNA
The CRISPR/Cas9 (type II CRISPR system; Jinek et al., 2012) genome-editing system comprises the Cas9 nuclease, a CRISPR RNA (crRNA) array that encodes the sgRNA, and a *trans*-activating crRNA (tracrRNA) that facilitates the processing of the crRNA array into discrete units. Each crRNA unit contains a 20-nucleotide guide sequence and a partial direct repeat, where the guide sequence directs the Cas9 to a 20-base-pair DNA target through Watson-Crick base pairing (Jinek et al., 2012). Upon co-expression, complex formation of the sgRNA with Cas9 nuclease will introduce a genomic DSB at the target site. With the predominantly used conventional CRISPR-Cas9 system derived from *S. pyogenes*, the target DNA must immediately precede a 5′-NGG PAM (Cong et al., 2013; Jinek et al., 2012; Mali et al., 2013; Figure 2B), although other Cas9 orthologs have different PAM requirements (Hou et al., 2013). CRISPR/Cas9-mediated targeting in hPSCs is more efficient than TALEN-mediated targeting (Ding et al., 2013b), and that efficiency can be further increased by multiplexing sgRNAs in a single genome-editing experiment (Mandal et al., 2014). Although the relatively short *S. pyogenes* PAM confers flexibility in target sequence selection (the PAM motif NGG is found every 8–12 base pairs on average for the human genome; Cong et al., 2013; Hsu et al., 2013), this targeting strategy is limited to NGG-proximal sequences. This may limit the use of CRISPR/Cas9 when target specificity is required, e.g., introducing a DSB at a precise sequence location for HDR-mediated repair of point mutations.

Non-canonical PAM sequences and Cas proteins derived from alternative bacteria have recently expanded the number of potential target sites (Hsu et al., 2013; Kleinstiver et al., 2015; Zetsche et al., 2015; Zhang et al., 2014). The efficacy of these alternative PAMs and Cas9 orthologs for hPSC genome editing remains to be determined.

Another important point to consider with the design of sgRNAs is the potential for off-target effects as the sgRNA is mismatch tolerant (Fu et al., 2013). Off-target indels found in CRISPR/Cas9 gene-editing experiments can be dramatically reduced using "truncated" sgRNAs that are 17 to 18 instead of 20 nucleotides long, without sacrificing on-target cutting efficiency. The utility of truncated sgRNAs may be target dependent as it has been postulated that truncated sgRNAs have a reduced binding affinity for their cognate sequence. This reduced binding affinity may in some cases result in reduced on-target activity of truncated sgRNAs (Fu et al., 2014). The same group and others also reported the use of an N-terminal fusion of FokI to a catalytically inactive Cas9 (dCas9) that requires dimerization of FokI monomers for DSB introduction necessitating two separate sgRNAs (targeting orthogonal DNA sequences) to introduce a DSB (Guilinger et al., 2014b; Tsai et al., 2014). Although longer sgRNAs have been used as well, the increase in specificity is minimal (Cho et al., 2014; Ran et al., 2013a). Another approach to reduce the likelihood of off-target effects and to increase on-target specificity is the use of a mutant "nickase" variant of Cas9. The Cas9-D10A mutant protein introduces a single-strand nick, instead of a DSB, which is repaired through HDR and not NHEJ. This will result in precise repair at the DNA nick without introduction of any indels (Cong et al., 2013; Mali et al., 2013; Figure 2C). This strategy of Cas9 nickase-mediated targeting has been used to generate hPSC-reporter cell lines (Merkle et al., 2015). Merkle et al. (2015) did find a number of loci that were targeted unsuccessfully, suggesting that gene knockins mediated by Cas9-D10A nickase activity are sequence or locus dependent. The use of a pair of Cas9-D10A nucleases, targeted to opposite DNA strands with separate gRNAs such that the nicks are less than 100 base pairs apart, essentially creates a DSB with 50- to 1,500-fold fewer off-target indels than wild-type Cas9 (Ran et al., 2013b; Figure 2C). Whole genome sequencing in CRISPR/Cas9 and TALEN genome-edited hPSCs revealed very high specificity and minimal genome mutational load with TALENs and truncated gRNAs, where nearly all of the mutations accumulated during regular hPSC culture (Smith et al., 2014; Suzuki et al., 2014; Veres et al., 2014).

Design of DNA Donor Templates for Gene Knockins

In contrast to the generation of hPSC gene knockout lines based on NHEJ, precise editing of point mutations, gene addition or deletion, and generation of reporter lines require an exogenous DNA template used by HDR to precisely engineer the genotype of interest (Jasin and Rothstein, 2013). The DNA template comprises left and right homology arms and an intervening DNA sequence that contains the DNA insert of interest (Capecchi, 1989). For the editing of point mutations or SNPs, ssODNs are preferable as a DNA template, because the sequence to be edited is generally very small (typically <5 nt mismatch between wild-type and repair template sequence).The homology arms can be kept short without affecting HDR-mediated gene-editing efficiency (Ding et al., 2013a, 2013b; Yang et al., 2013), although

others have reported variability in targeting efficiency using ssODNs (Radecke et al., 2010). Design of ssODNs is straightforward, and they can be synthesized commercially, which is very cost-effective. Adeno-associated virus (AAV) vectors have also been successfully used as HDR-repair templates to introduce mutations at multiple genomic loci in hPSCs (Khan et al., 2010; Li et al., 2012) and hematopoietic stem cells (Ellis et al., 2013).

There is a correlation between the size of the sequence load and the length of the homology arms that determines the efficiency of HDR-mediated genome editing (Radecke et al., 2010). HDR-mediated introduction of a bigger sequence load such as a reporter gene or gene replacement requires longer homology arms. It has been reported that HDR-mediated genome editing is improved by using homology arms of 400 base pairs or longer (Hendel et al., 2014; Merkle et al., 2015). Also, sequence divergence between homology arms of the repair template and chromosomal locus targeted should ideally be less than 2% to avoid decrease in HDR-mediated targeting (Elliott et al., 1998), making it important to sequence the homology regions spanning the locus in each cell line to be targeted. In order to prevent re-cutting of the edited sequence after successful insertion, it is recommended to introduce a silent mutation in the TALEN- or sgRNA-binding site.

Another important DNA template design consideration is the location of the intended mutation up- or downstream of the DSB. The so-called "conversion tract" or distance between mutation and DSB should be as short as possible and in general less than 50 base pairs, beyond which the HDR-mediated repair efficiency drops dramatically (Elliott et al., 1998; Yang et al., 2013). Introduction of a silent mutation that adds or removes a restriction endonuclease cut site in the ssODN can aid in mutation analysis and clone screening. To optimally pursue this strategy, this additional mismatch should also be less than ten nucleotides away from the DSB site (Yang et al., 2013).

Analysis of Nuclease Cutting Efficiency

When designing ideal NHEJ-mediated gene knockout or HDR-mediated SNP repair strategies, the percentage of nuclease activity as determined by gel-based assay of highly active nucleases should ideally be greater than 25% when assessed in HEK293T or U2OS cells and under optimal delivery conditions (Hendel et al., 2015a). Although the nuclease activity depends on multiple parameters such as cell type, target, and delivery method, the 25% cutting efficiency determined in HEK293T or U2OS, in our hands, generally translates to efficient nuclease activity in hPSCs. Should your engineered nucleases prove less efficient than this goal, one strategy for improvement of nuclease activity is to "cold-shock" the transfected cells at 30°C for 24 hr. This treatment improved ZFN-mediated DSB introduction in mammalian cell lines and has been used to improve TALEN activity in embryonic stem cells as well (Carlson et al., 2012; Doyon et al., 2010). We and others, however, do not routinely culture TALEN- or CRISPR/Cas9-transfected hPSCs at this temperature as it also affects the growth of cells. Higher nuclease activity is generally better for successful genome-editing experiments. In certain circumstances, especially for HDR-mediated editing events, the flexibility in TALEN or CRISPR gRNA design can be limited. Gene-editing application and DNA sequence permitting, we generally design and test at least three guide RNAs or two to

three TALEN plasmid pairs and use the most-active engineered nuclease for hPSC-targeting experiments.

The nuclease activity of any given TALEN or CRISPR/Cas9 determines the efficiency of site-specific DSB introduction and subsequent targeting events at loci of interest. Because delivery of TALENs or CRISPR gRNAs in hPSCs is inefficient (see below), evaluation of nuclease activity is typically tested in an easy to transfect cell line, such as the U2OS or HEK239T cell lines. Because transfection in these cell lines is more efficient, cleavage efficiency is much higher compared with hPSCs. In general, a mutation efficiency of at least 25% in a gel-based cleavage assay is necessary to successfully use the tested TALEN or sgRNA in an hPSC-targeting experiment. This is dependent upon the target locus; we have found sgRNAs with high cleavage efficiency in HEK293T cells that did not introduce DSBs in hPSCs. This may be due to target locus accessibility, the target sequence itself, or differences in the DNA damage response between hPSCs and immortalized somatic cell lines (Chari et al., 2015; Liu et al., 2014). The mutations generated by NHEJ after introduction of nuclease-induced DSBs usually range from one to tens of inserted or deleted nucleotides. Detecting these indels provides a quantitative (indirect) measurement of TALEN- or CRISPR/Cas9-mediated cleavage activity. Our labs primarily use a gel-based mutation detection assay with the CEL-I nuclease (Surveyor assay) or T7 endonuclease I (T7EI), which is rapid and cost effective. These assays rely on in vitro melting and annealing of mutant and wild-type genomic DNA followed by recognition and cleavage of resultant mismatches by exogenous endonucleases. T7E1 endonuclease is more sensitive and has a lower detection limit for cleaved mutant alleles than does the Surveyor assay (Sakurai et al., 2014; Vouillot et al., 2015). Gel-based mutation assays cannot readily detect indels less abundant than 1% or 2% of the genetic population and are unable to demonstrate the type of indel introduced (Hendel et al., 2015a). Digital droplet PCR (ddPCR)-based methods can also be used to accurately analyze NHEJ and HDR events as a measure for nuclease cutting efficiency (Miyaoka et al., 2014). This method uses a reference probe to detect a genomic region distant from the DSB and a second labeled probe designed to bind wild-type DNA at the predicted cut site. The decrease in signal from the DSB-targeted probe is a measure for nuclease cleavage efficiency (abstract by Berman et al., 2015). Sequencing-based techniques, such as Sanger and NGS sequencing, are also used to analyze mutagenic NHEJ events and are more sensitive than gel-based mutation detection assays. A simple and cost-effective in silico method to evaluate CRISPR/Cas9-mediated cleavage efficiency is tracking of indels by decomposition (TIDE) (Brinkman et al., 2014). Here, two Sanger sequence traces, one from a control and another from a sgRNA-transfected genomic DNA PCR sample, are uploaded and analyzed by a decomposition algorithm (Brinkman et al., 2014). In addition, NGS approaches can detect mutation frequencies up to 0.007% and give direct information about the indel sequence (Chen et al., 2013; Yang et al., 2013). One disadvantage is that sequence-based assays use relatively short PCR amplicons to evaluate indel frequency that can lead to underestimation of the number of indels, especially when larger insertions or deletions are introduced that fall outside the PCR amplicon boundaries (due to read-length limitations).

An alternative technique to track genome engineering outcome in mammalian cells has been developed called the traffic light reporter, which generates a flow cytometric readout of HDR-mediated gene targeting and NHEJ-mediated gene disruption (Certo et al., 2011). Although this technique provides a simple, rapid, and quantitative readout, the prerequisite generation of a reporter gene prevents measurement at endogenous target loci. The use of the traffic light reporter system has not yet been reported in hPSCs. Some other less-popular methods of indirect quantitative mutation assays are fluorescent PCR assays, DNA melting analysis, and restriction fragment length polymorphism (RFLP) analysis (Hendel et al., 2015a), although the latter is often used for detecting HDR-mediated editing events (Ding et al., 2013a; Ran et al., 2013a). A recently developed method for analyzing gene-editing outcomes in hPSCs, single-molecule real-time (SMRT) sequencing, has been reported to allow quantification of HDR-mediated gene-editing events using plasmid DNA templates with long arms of homology (Hendel et al., 2014).

Nuclease Delivery into hPSCs
Having carefully designed and successfully generated active TALENs or CRISPR gRNAs, the next step in the hPSC genome-editing workflow is delivery of the nucleases into hPSCs (Figure 1). This can be challenging and often involves selection or enrichment of successfully transfected cells, either by FACS or antibiotic selection (Ding et al., 2013a; Hockemeyer et al., 2011). TALE or CRISPR/Cas9 nucleases can be delivered to hPSCs in the form of DNA, RNA, or protein.

Delivery as DNA
TALENs are primarily delivered as a combination of two DNA plasmids, with a 5′ TALE-binding array fused to a FokI-nuclease monomer on one plasmid, whereas the other contains a 3′ TALE-binding array also fused to a FokI-nuclease monomer (Christian et al., 2010; Miller et al., 2011). The CRISPR/Cas9 genome-editing system delivered as DNA comprises either two plasmids, one containing the Cas9 nuclease and one the CRISPR gRNA (Mali et al., 2013), or one plasmid containing both the Cas9 nuclease and CRISPR gRNA in a single expression cassette (Ran et al., 2013a). The advantages of using DNA delivery of TALENs and CRISPR/Cas9 gRNA is the relatively straightforward cloning and the high efficiency in generating NHEJ-mediated knockout hPSC lines (Ding et al., 2013a, 2013b). On the other hand, the use of plasmid DNA nuclease delivery, especially with Cas9, has been associated with unwanted off-target indels (Merkle et al., 2015).

Delivery as RNA
TALEN mRNA delivery for gene editing in hPSCs has, to our knowledge, not yet been reported, although TALEN mRNA delivery to mouse embryonic stem cells has been successful in generation of transgenic (knockout) mice (Wefers et al., 2013). CRISPR/Cas9 delivered as mRNA has been used for targeting hPSCs (Kim et al., 2014). Although not yet reported in hPSC gene editing, chemically modified guide RNAs enhance CRISPR/Cas9 genome-editing efficiency in human primary cells, such as T cells and CD34+ HSCs (Hendel et al., 2015b), and may further increase gene targeting efficiencies in hPSCs. Compared with plasmid delivery, mRNA transfection of CRISPR/Cas9 leads to faster expression and avoids unwanted

integration of plasmid DNA encoding the nuclease(s) (Kim et al., 2014).

Delivery as Protein

To our knowledge, only one study used direct protein administration of TALENs fused to the protein transduction peptide TAT. This study targeted the CCR5 locus in hPSCs with an efficiency of 5% (Ru et al., 2013). On the other hand, direct protein delivery of Cas9 nuclease complexed with in-vitro-transcribed sgRNA (mRNA) has been widely successful in hPSC genome editing. The greatest advantage of protein delivery is quick degradation upon delivery, resulting in a dramatic reduction of off-target indels (D'Astolfo et al., 2015; Kim et al., 2014; Liang et al., 2015; Zuris et al., 2015).

In addition to optimization of delivery vector (DNA, RNA, or protein) for custom-engineered endonucleases, the choice of delivery technique is equally important with hard to transfect cells like hPSCs. A few delivery techniques have been successfully applied in genome engineering of hPSCs. Electroporation as delivery technique for gene targeting in hPSCs has been successfully used in many studies (Ding et al., 2013a; Hockemeyer et al., 2011; Hou et al., 2013; Zwaka and Thomson, 2003). The most-important disadvantage of this delivery technique is the massive amount of cell death that occurs after electroporation, necessitating a high input of hPSCs, usually around 1×10^7 cells per electroporation. Since the first electroporations of hPSCs for gene-editing purposes (Zwaka and Thomson, 2003), methods have been improved, especially with regard to efficiency using single-cell hPSC suspensions (Costa et al., 2007) and improved survival using the Rho kinase (ROCK) inhibitor Y-23672 (Watanabe et al., 2007). Nucleofection, a modified electroporation technique, is an efficient method to deliver gene targeting and nuclease constructs to hPSCs (Byrne et al., 2015; Cai et al., 2007; Ran et al., 2013b; Sanjana et al., 2012; Yang et al., 2013). Recently, Cas9 protein and gRNA riboprotein complexes have been delivered using nucleofection, resulting in efficient gene editing, while reducing off-target mutations (Kim et al., 2014; Lin et al., 2014). Fewer hPSCs are needed for nucleofection compared with conventional electroporation, typically in the range of 0.5–2.0 million cells per electroporation. The disadvantage is that nucleofection requires more optimization of the electrical parameters with cell-type-specific reagents, which can be less cost effective. Cationic lipid-based transfection reagents are widely used as a carrier for genetic material delivery into a variety of eukaryotic cells because of their efficiency and ease of use. Cationic lipid delivery of plasmid DNA into hPSCs has been very inefficient, though there are reports describing lipid-based transfection of hPSCs (Cai et al., 2007; Ma et al., 2012). We have recently developed an hPSC transfection protocol using a new lipid-based formulation, Lipofectamine 3000, that allows for efficient transfection and better cell survival of transfected hPSCs (Hendriks et al., 2015). Cas9 protein has been efficiently delivered to mouse ESCs using cationic lipids, though this method has not yet been applied to nuclease delivery in hPSCs. A novel protein-transduction method based on osmolarity and a transduction protein inducing macropinocytosis has recently been used to deliver gRNA and Cas9 protein to hPSCs. This method, "induced transduction by osmocytosis and propanebetaine" (iTOP), resulted in a more than 25% gene editing rate in H1 ESCs (D'Astolfo et al., 2015). Like other protein trans-

duction methods, iTOP-mediated CRISPR/Cas9 expression is transient, assuring that the gene-editing system does not persist in the cell, avoiding off-target indels. Viral vector-mediated delivery of CRISPR/Cas9 gene-editing constructs into hPSCs has been successful, especially non-integrating viral vectors such as adenovirus and baculovirus (Zhu et al., 2013). In addition, the smaller *S. aureus*-derived Cas9 has recently been packaged in an AAV vector that has a relatively small packaging capacity (4.7–4.8 kb). Lentiviral delivery of TALENs is inefficient, due in part to the viral reverse transcriptase that has difficulties transcribing the repetitive sequences within the TALE DNA-binding array (Holkers et al., 2012). On the other hand, successful lentiviral delivery of CRISPR/Cas9 constructs and subsequent gene editing has been shown in a number of studies (Kabadi et al., 2014; Shalem et al., 2014).

Genome-Edited Cell Selection and Genotyping

Upon successful delivery of custom-engineered nucleases into hPSCs, the final step in a typical hPSC gene-editing workflow is the selection of clonal gene-edited hPSCs. Depending on the type of targeting experiment, this can be achieved several ways. The TALEN and CRISPR/Cas9 constructs commonly used in our labs for hPSC genome engineering contain fluorescent reporters that enable enrichment of transfected hPSCs by FACS (Figure 3A). Although a dedicated FACS sorter would be ideal to avoid potential mycoplasma contamination often seen with shared FACS sorters, our labs do use FACS-sorting core facilities. We typically add Mycozap or Plasmocin to the cell culture media for 24 hr post-FACS. Reporter-positive cells are plated at a limiting dilution, allowing the formation of single-cell-derived colonies. These single-cell-derived colonies should be carefully monitored during their growth to avoid merged colonies, which will result in mixed genotypes upon expansion. Each colony is picked when it becomes about >500 μm in diameter and plated into one well of a 96-well plate (Ding et al., 2013a; Hendriks et al., 2015; Peters et al., 2008). Upon reaching confluence, the plate is split into two plates, one clone recovery plate and one plate for genomic DNA isolation for subsequent clone genotyping (Figure 1). Clones are analyzed by PCR amplification of a region surrounding the nuclease target site (DSB site) and subsequent analysis of PCR amplicons on a high-percentage agarose gel to identify edited hPSC clones. Targeted clones with potential frameshift-causing indels are identified by a band shift, indicating indel production (Figure 3B). HDR-mediated precise introduction of (single) base substitutions can be detected by RFLP if the ssODN used as donor template introduces or removes a restriction endonuclease site (Ding et al., 2013a; Figure 3B). Positive clones are then Sanger sequenced for genotype confirmation and identification (Figure 3C).

An elegant method for isolating genome-edited hPSC lines containing point mutations or single-base substitutions was reported recently. This method uses ddPCR and sib selection followed by subdivision of the targeted hPSC population until the rare correctly targeted hPSC clone can be isolated (Miyaoka et al., 2014). Less hands-on time and no need for antibiotic selection are the main advantages of this method. ddPCR has been used to generate 20 targeted hPSC knockin lines with single-base substitutions in a relatively short period of time

Figure 3. Genome-Edited hPSC Selection and Genotyping
(A) Example of FACS enrichment of transfected hPSCs. Left panel shows mock electroporated hPSCs with no GFP-positive cells, whereas the right panel shows hPSCs electroporated with sgRNA and Cas9-GFP.
(B) NHEJ-mediated indel formation in FACS-enriched hPSCs creates heterozygous and homozygous frame shift, causing mutations resulting in gene knockout. Alternatively, co-expression of an ssODN containing a SNP and a restriction enzyme site, with Cas9-GFP and a sgRNA, results in HDR-mediated introduction of the SNP in the hPSC genome.
(C) Upon PCR screening of FACS-enriched hPSCs, Sanger sequencing of positive clones confirms and identifies genotype. Shown are potential outcomes after gene editing with Cas9-GFP and a sgRNA.

(Miyaoka et al., 2014). Another recently developed hPSC genome-editing assessment tool is based on next-generation sequencing (Yang et al., 2013). This genome-editing assessment system (GEAS) quantitates gene-editing efficiency with HDR being measured by the percentage of reads containing precise base pair mismatches, whereas NHEJ efficiency is measured by the percentage of reads carrying indels (Yang et al., 2013). The main advantage of this approach is its sensitivity, as it can detect HDR rates of down to 0.007% (Yang et al., 2013). In the sib-selection method (Miyaoka et al., 2014), with each round of ddPCR, one well of a 96-well plate with the highest percentage of targeted cells is passaged to a new 96-well plate and so on. In contrast, the GEAS method relies on a priori HDR assessment in an hPSC population (Yang et al., 2013). This latter method has the advantage of not only detecting single-base-pair substitutions but also other types of precisely engineered indels or knockins. In addition, the advantage of GEAS over gel-based analysis of hPSC gene knockout clones (NHEJ) is that GEAS is able to detect single-base indels, whereas the gel-based method has a much-lower resolution of down to five to ten bases. Genome-edited cell lines can be frozen for preservation upon expansion from the 96-well plate into larger cell culture vessels or as 96 colonies within the 96-well microplate itself.

Conclusions
The field of genome engineering is rapidly evolving due to new technological developments. The ability to combine human pluripotent-stem-cell-based technology with state-of-the-art gene editing technology is impacting basic and applied biology research by generating better in vitro disease models, chemical screens, and cell-based therapies. Though genome editing in human pluripotent stem cells has historically been very difficult due to the inefficiency of HDR in hPSCs (Zwaka and Thomson, 2003), the development of custom-engineered endonucleases to precisely target DNA DSBs substantially increased the efficiency of HDR-based gene editing in hPSCs (Ding et al., 2013b; Hockemeyer et al., 2009, 2011). HDR-based gene editing can be further augmented by modulating the NHEJ pathway (Chu et al., 2015; Maruyama et al., 2015; Yu et al., 2015).

The desired type of gene mutation, insertion, or deletion dictates the type of custom-engineered nuclease to use as well as the design of its DNA-binding domain (TALEN) or CRISPR guide RNA (CRISPR/Cas9) and DNA donor template (Table 2). Although TALENs have been used very successfully to genome engineer hPSCs, their popularity as a gene-editing tool in hPSCs is dwindling mainly due to the ease and versatility of the CRISPR/Cas9 platform. Most importantly, the CRISPR/Cas9 system more efficiently generates indels at the target site than do

Table 2. Considerations and Recommendations for hPSC Gene Editing using TALEN and CRISPR/Cas9

Locus accessibility	Locus accessibility for the TALEN or CRISPR/Cas9 nuclease is critical, as it determines cleavage activity to a great extent. If permitted, avoid 5mC present in CpG islands when using TALENs. For both TALEN and CRISPR/Cas9 nucleases, avoid regions that are DNaseI hyposensitive.	Hsu et al., 2013; Chari et al., 2015; Valton et al., 2012
"Safe harbor" loci	Ubiquitous transcribed loci in hPSCs such as the AAVS1 on Chr. 19 and H11 on Chr. 22 are relatively easy to target for gene engineering without affecting hPSC growth and proliferation. These loci are often used to insert reporter genes.	Hockemeyer et al., 2011; Luo et al., 2014; Zhu et al., 2014
Gene-editing event—gene KO	Target start codon and avoid sites in the end of coding sequence. Choose target site residing in common exon.	Kim et al., 2013
Gene-editing event—single base substitution	CRISPR/Cas9 or TALEN in combination with the use of ssODNs are very efficient to generate hPSC lines with single base substitutions. Inclusion of a silent mutation encoding or removing a RE site helps with screening gene-edited clones using conventional PCR. If possible, design ssODNs that destroy the PAM site or TALEN DNA binding site to avoid indel generation after successful gene editing.	Ding et al., 2013a, 2013b; Miyaoka et al., 2014; Merkle et al., 2015
Gene-editing event—larger deletions, generation of reporter lines	Efficient TALENs have been described for HDR-mediated integration of gene cassettes, in particular for the AAVS1 locus. CRISPR/Cas9 remains a very efficient nuclease for this purpose. Use of long homology arms with plasmid DNA templates is key for successful cassette integration. Physical separation of CRISPR/dual Cas9 nickase target sites through gene insertion will reduce on-target indel formation.	Hockemeyer et al., 2011; Merkle et al., 2015; Hendel et al., 2014
Nuclease cutting efficiency	Test two to three TALENs or sgRNAs in easy to transfect cell line. In general, at least 25% cutting efficiency should be observed for successful subsequent gene editing in hPSCs.[a]	Hendel et al., 2015a; Hendriks et al., 2015
Nuclease delivery vector	Ideally, Cas9 nuclease should be delivered as protein (complexed with in-vitro-transcribed sgRNA) or mRNA to avoid on- and off-target cleavage due to prolonged Cas9 expression when delivered as plasmid DNA.	D'Astolfo et al., 2015; Zuris et al., 2015; Kim et al., 2014
Nuclease delivery method	Electroporation of nucleases and sgRNA is efficient and relatively cost-effective but requires ten times more hPSCs than nucleofection or transfection. Depending on the hPSC line used, settings for both electroporation and nucleofection may require (extensive) optimization, whereas the newer-generation lipid-based transfection reagents are cost-effective regarding their ease of use and amount of hPSCs/reagents needed.	Zwaka and Thomson, 2003; Cai et al., 2007; Ma et al., 2012; Hendriks et al., 2015

[a]This is a general guideline; not all successful cleaving sgRNAs or TALENs tested in, e.g., 293Ts, will cleave successfully in hPSCs (locus dependent).

TALENs targeting the same locus in hPSCs (Ding et al., 2013b; Merkle et al., 2015). One major disadvantage of the CRISPR/Cas9 system compared to TALENs is the bigger potential for off-target cutting because of mismatch tolerance of the guide RNAs (Fu et al., 2013). A number of guide RNA and Cas9 design adjustments decrease off-target cleavage of the CRISPR/Cas9 system dramatically (Fu et al., 2014; Hsu et al., 2013; Merkle et al., 2015; Ran et al., 2013b).

Sustained expression of CRISPR guide RNAs and Cas9 nuclease from transfected plasmid DNA can exacerbate both off- and on-target nuclease activities. Delivery of custom-engineered nucleases either as mRNA or protein is as efficient as plasmid DNA-derived nuclease in targeting hPSC loci while decreasing off-target indel accumulation (Kim et al., 2014; Liang et al., 2015). Three studies have been published recently showing a near absence of off-target cleavage after targeting hPSCs with TALENs and CRISPR/Cas9 and subsequent genome-wide sequence analysis (Smith et al., 2014; Suzuki et al., 2014; Veres et al., 2014). Most SNPs and indels found in these studies are attributed to prolonged culture of hPSC lines.

Powerful applications of the CRISPR/Cas9 gene-editing platform are under constant innovation. Whole-genome gRNA libraries (genome-wide CRISPR knockout screen [GeCKO]) have been used to dissect gene function in hPSCs (Shalem et al., 2014). The ubiquitous transcribed AAVS1 "safe harbor" locus has been used to introduce a Cas9-GFP cassette under a doxycycline-inducible promoter in different hPSC lines, resulting in inducible genome editing with transient expression of Cas9 (González et al., 2014). These and other innovative applications of the CRISPR/Cas9 system are changing the face of in vitro genetics studies.

In this protocol review, we have described a general TALEN- and CRISPR/Cas9-based hPSC genome-editing workflow and pointed out experimental considerations. Although this review

primarily focuses on the use of TALEN and the *S. pyogenes* Cas9 nuclease, a new repertoire of TALE RVDs (Miller et al., 2015) and new orthologs of Cas9 nucleases and their cognate PAM sites (Hou et al., 2013; Kleinstiver et al., 2015; Ran et al., 2015) will ultimately allow targeting any genomic locus for sequence engineering. In combination with improvements in nuclease delivery methods for hPSC engineering, the TALEN and CRISPR/Cas9 gene-editing platforms now present a formidable molecular toolbox to study stem cell biology and improve hPSC-based disease models.

REFERENCES

Bae, S., Park, J., and Kim, J.S. (2014). Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics *30*, 1473–1475.

Bibikova, M., Beumer, K., Trautman, J.K., and Carroll, D. (2003). Enhancing gene targeting with designed zinc finger nucleases. Science *300*, 764.

Boch, J., Scholze, H., Schornack, S., Landgraf, A., Hahn, S., Kay, S., Lahaye, T., Nickstadt, A., and Bonas, U. (2009). Breaking the code of DNA binding specificity of TAL-type III effectors. Science *326*, 1509–1512.

Bock, C., Kiskinis, E., Verstappen, G., Gu, H., Boulting, G., Smith, Z.D., Ziller, M., Croft, G.F., Amoroso, M.W., Oakley, D.H., et al. (2011). Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell *144*, 439–452.

Boulting, G.L., Kiskinis, E., Croft, G.F., Amoroso, M.W., Oakley, D.H., Wainger, B.J., Williams, D.J., Kahler, D.J., Yamaki, M., Davidow, L., et al. (2011). A functionally characterized test set of human induced pluripotent stem cells. Nat. Biotechnol. *29*, 279–286.

Brinkman, E.K., Chen, T., Amendola, M., and van Steensel, B. (2014). Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. *42*, e168.

Bultmann, S., Morbitzer, R., Schmidt, C.S., Thanisch, K., Spada, F., Elsaesser, J., Lahaye, T., and Leonhardt, H. (2012). Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. Nucleic Acids Res. *40*, 5368–5377.

Byrne, S.M., Ortiz, L., Mali, P., Aach, J., and Church, G.M. (2015). Multi-kilobase homozygous targeted gene replacement in human induced pluripotent stem cells. Nucleic Acids Res. *43*, e21.

Cai, L., Ye, Z., Zhou, B.Y., Mali, P., Zhou, C., and Cheng, L. (2007). Promoting human embryonic stem cell renewal or differentiation by modulating Wnt signal and culture conditions. Cell Res. *17*, 62–72.

Canver, M.C., Bauer, D.E., Dass, A., Yien, Y.Y., Chung, J., Masuda, T., Maeda, T., Paw, B.H., and Orkin, S.H. (2014). Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. J. Biol. Chem. *289*, 21312–21324.

Capecchi, M.R. (1989). Altering the genome by homologous recombination. Science *244*, 1288–1292.

Carlson, D.F., Tan, W., Lillico, S.G., Stverakova, D., Proudfoot, C., Christian, M., Voytas, D.F., Long, C.R., Whitelaw, C.B., and Fahrenkrug, S.C. (2012). Efficient TALEN-mediated gene knockout in livestock. Proc. Natl. Acad. Sci. USA *109*, 17382–17387.

Cermak, T., Doyle, E.L., Christian, M., Wang, L., Zhang, Y., Schmidt, C., Baller, J.A., Somia, N.V., Bogdanove, A.J., and Voytas, D.F. (2011). Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. *39*, e82.

Certo, M.T., Ryu, B.Y., Annis, J.E., Garibov, M., Jarjour, J., Rawlings, D.J., and Scharenberg, A.M. (2011). Tracking genome engineering outcome at individual DNA breakpoints. Nat. Methods *8*, 671–676.

Chari, R., Mali, P., Moosburner, M., and Church, G.M. (2015). Unraveling CRISPR-Cas9 genome engineering parameters via a library-on-library approach. Nat. Methods *12*, 823–826.

Chen, S., Oikonomou, G., Chiu, C.N., Niles, B.J., Liu, J., Lee, D.A., Antoshechkin, I., and Prober, D.A. (2013). A large-scale in vivo analysis reveals that TALENs are significantly more mutagenic than ZFNs generated using context-dependent assembly. Nucleic Acids Res. *41*, 2769–2778.

Chen, W., Liu, J., Zhang, L., Xu, H., Guo, X., Deng, S., Liu, L., Yu, D., Chen, Y., and Li, Z. (2014). Generation of the SCN1A epilepsy mutation in hiPS cells using the TALEN technique. Sci. Rep. *4*, 5404.

Cho, S.W., Kim, S., Kim, Y., Kweon, J., Kim, H.S., Bae, S., and Kim, J.S. (2014). Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. *24*, 132–141.

Choulika, A., Perrin, A., Dujon, B., and Nicolas, J.F. (1995). Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae. Mol. Cell. Biol. *15*, 1968–1973.

Christian, M., Cermak, T., Doyle, E.L., Schmidt, C., Zhang, F., Hummel, A., Bogdanove, A.J., and Voytas, D.F. (2010). Targeting DNA double-strand breaks with TAL effector nucleases. Genetics *186*, 757–761.

Chu, V.T., Weber, T., Wefers, B., Wurst, W., Sander, S., Rajewsky, K., and Kühn, R. (2015). Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nature Biotechnology *33*, 543–548.

Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., and Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science *339*, 819–823.

Costa, M., Dottori, M., Sourris, K., Jamshidi, P., Hatzistavrou, T., Davis, R., Azzola, L., Jackson, S., Lim, S.M., Pera, M., et al. (2007). A method for genetic modification of human embryonic stem cells using electroporation. Nat. Protoc. *2*, 792–796.

Cradick, T.J., Qiu, P., Lee, C.M., Fine, E.J., and Bao, G. (2014). COSMID: a web-based tool for identifying and validating CRISPR/Cas off-target sites. Mol. Ther. Nucleic Acids *3*, e214.

D'Astolfo, D.S., Pagliero, R.J., Pras, A., Karthaus, W.R., Clevers, H., Prasad, V., Lebbink, R.J., Rehmann, H., and Geijsen, N. (2015). Efficient intracellular delivery of native proteins. Cell *161*, 674–690.

Ding, Q., Lee, Y.K., Schaefer, E.A., Peters, D.T., Veres, A., Kim, K., Kuperwasser, N., Motola, D.L., Meissner, T.B., Hendriks, W.T., et al. (2013a). A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell *12*, 238–251.

Ding, Q., Regan, S.N., Xia, Y., Oostrom, L.A., Cowan, C.A., and Musunuru, K. (2013b). Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell *12*, 393–394.

Doyle, E.L., Booher, N.J., Standage, D.S., Voytas, D.F., Brendel, V.P., Vandyk, J.K., and Bogdanove, A.J. (2012). TAL effector-nucleotide targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction. Nucleic Acids Res. *40*, W117–W122.

Doyon, Y., Choi, V.M., Xia, D.F., Vo, T.D., Gregory, P.D., and Holmes, M.C. (2010). Transient cold shock enhances zinc-finger nuclease-mediated gene disruption. Nat. Methods *7*, 459–460.

Elliott, B., Richardson, C., Winderbaum, J., Nickoloff, J.A., and Jasin, M. (1998). Gene conversion tracts from double-strand break repair in mammalian cells. Mol. Cell. Biol. *18*, 93–101.

Ellis, B.L., Hirsch, M.L., Porter, S.N., Samulski, R.J., and Porteus, M.H. (2013). Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration-approved drugs. Gene Ther. *20*, 35–42.

Engler, C., Gruetzner, R., Kandzia, R., and Marillonnet, S. (2009). Golden gate shuffling: a one-pot DNA shuffling method based on type IIs restriction enzymes. PLoS ONE 4, e5553.

Fine, E.J., Cradick, T.J., Zhao, C.L., Lin, Y., and Bao, G. (2014). An online bioinformatics tool predicts zinc finger and TALE nuclease off-target cleavage. Nucleic Acids Res. 42, e42.

Frank, S., Skryabin, B.V., and Greber, B. (2013). A modified TALEN-based system for robust generation of knock-out human pluripotent stem cell lines and disease models. BMC Genomics 14, 773.

Fu, Y., Foden, J.A., Khayter, C., Maeder, M.L., Reyon, D., Joung, J.K., and Sander, J.D. (2013). High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822–826.

Fu, Y., Sander, J.D., Reyon, D., Cascio, V.M., and Joung, J.K. (2014). Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat. Biotechnol. 32, 279–284.

González, F., Zhu, Z., Shi, Z.D., Lelli, K., Verma, N., Li, Q.V., and Huangfu, D. (2014). An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell 15, 215–226.

Grskovic, M., Javaherian, A., Strulovici, B., and Daley, G.Q. (2011). Induced pluripotent stem cells–opportunities for disease modelling and drug discovery. Nat. Rev. Drug Discov. 10, 915–929.

Guilinger, J.P., Pattanayak, V., Reyon, D., Tsai, S.Q., Sander, J.D., Joung, J.K., and Liu, D.R. (2014a). Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat. Methods 11, 429–435.

Guilinger, J.P., Thompson, D.B., and Liu, D.R. (2014b). Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat. Biotechnol. 32, 577–582.

Heigwer, F., Kerr, G., Walther, N., Glaeser, K., Pelz, O., Breinig, M., and Boutros, M. (2013). E-TALEN: a web tool to design TALENs for genome engineering. Nucleic Acids Res. 41, e190.

Heigwer, F., Kerr, G., and Boutros, M. (2014). E-CRISP: fast CRISPR target site identification. Nat. Methods 11, 122–123.

Hendel, A., Kildebeck, E.J., Fine, E.J., Clark, J.T., Punjya, N., Sebastiano, V., Bao, G., and Porteus, M.H. (2014). Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing. Cell Rep. 7, 293–305.

Hendel, A., Fine, E.J., Bao, G., and Porteus, M.H. (2015a). Quantifying on- and off-target genome editing. Trends Biotechnol. 33, 132–140.

Hendel, A., Bak, R.O., Clark, J.T., Kennedy, A.B., Ryan, D.E., Roy, S., Steinfeld, I., Lunstad, B.D., Kaiser, R.J., Wilkens, A.B., et al. (2015b). Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985–989.

Hendriks, W.T., Jiang, X., Daheron, L., and Cowan, C.A. (2015). TALEN- and CRISPR/Cas9-mediated gene editing in human pluripotent stem cells using lipid-based transfection. Curr. Protoc. Stem Cell Biol. 34, 5B.3.1–5B.3.25.

Heyer, W.D., Ehmsen, K.T., and Liu, J. (2010). Regulation of homologous recombination in eukaryotes. Annu. Rev. Genet. 44, 113–139.

Hockemeyer, D., Soldner, F., Beard, C., Gao, Q., Mitalipova, M., DeKelver, R.C., Katibah, G.E., Amora, R., Boydston, E.A., Zeitler, B., et al. (2009). Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 27, 851–857.

Hockemeyer, D., Wang, H., Kiani, S., Lai, C.S., Gao, Q., Cassady, J.P., Cost, G.J., Zhang, L., Santiago, Y., Miller, J.C., et al. (2011). Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 29, 731–734.

Holkers, M., de Vries, A.A., and Gonçalves, M.A. (2012). Nonspaced inverted DNA repeats are preferential targets for homology-directed gene repair in mammalian cells. Nucleic Acids Res. 40, 1984–1999.

Hou, Z., Zhang, Y., Propson, N.E., Howden, S.E., Chu, L.F., Sontheimer, E.J., and Thomson, J.A. (2013). Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc. Natl. Acad. Sci. USA 110, 15644–15649.

Hsu, P.D., Scott, D.A., Weinstein, J.A., Ran, F.A., Konermann, S., Agarwala, V., Li, Y., Fine, E.J., Wu, X., Shalem, O., et al. (2013). DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827–832.

Jankele, R., and Svoboda, P. (2014). TAL effectors: tools for DNA targeting. Brief. Funct. Genomics 13, 409–419.

Jasin, M., and Rothstein, R. (2013). Repair of strand breaks by homologous recombination. Cold Spring Harb. Perspect. Biol. 5, a012740.

Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., and Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821.

Kabadi, A.M., Ousterout, D.G., Hilton, I.B., and Gersbach, C.A. (2014). Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Res. 42, e147.

Karagiannis, P., and Yamanaka, S. (2014). The fate of cell reprogramming. Nat. Methods 11, 1006–1008.

Khan, I.F., Hirata, R.K., Wang, P.R., Li, Y., Kho, J., Nelson, A., Huo, Y., Zavaljevski, M., Ware, C., and Russell, D.W. (2010). Engineering of human pluripotent stem cells by AAV-mediated gene targeting. Mol. Ther. 18, 1192–1199.

Kim, H., and Kim, J.S. (2014). A guide to genome engineering with programmable nucleases. Nat. Rev. Genet. 15, 321–334.

Kim, Y., Kweon, J., Kim, A., Chon, J.K., Yoo, J.Y., Kim, H.J., Kim, S., Lee, C., Jeong, E., Chung, E., et al. (2013). A library of TAL effector nucleases spanning the human genome. Nat. Biotechnol. 31, 251–258.

Kim, S., Kim, D., Cho, S.W., Kim, J., and Kim, J.S. (2014). Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24, 1012–1019.

Kleinstiver, B.P., Prew, M.S., Tsai, S.Q., Topkar, V.V., Nguyen, N.T., Zheng, Z., Gonzales, A.P., Li, Z., Peterson, R.T., Yeh, J.R., et al. (2015). Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523, 481–485.

Lamb, B.M., Mercer, A.C., and Barbas, C.F., 3rd (2013). Directed evolution of the TALE N-terminal domain for recognition of all 5′ bases. Nucleic Acids Res. 41, 9779–9785.

Li, L.B., Chang, K.H., Wang, P.R., Hirata, R.K., Papayannopoulou, T., and Russell, D.W. (2012). Trisomy correction in Down syndrome induced pluripotent stem cells. Cell Stem Cell 11, 615–619.

Li, Y., Wang, H., Muffat, J., Cheng, A.W., Orlando, D.A., Lovén, J., Kwok, S.M., Feldman, D.A., Bateup, H.S., Gao, Q., et al. (2013). Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell 13, 446–458.

Liang, X., Potter, J., Kumar, S., Zou, Y., Quintanilla, R., Sridharan, M., Carte, J., Chen, W., Roark, N., Ranganathan, S., et al. (2015). Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J. Biotechnol. 208, 44–53.

Lin, S., Staahl, B.T., Alla, R.K., and Doudna, J.A. (2014). Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. eLife 3, e04766.

Liu, J.C., Lerou, P.H., and Lahav, G. (2014). Stem cells: balancing resistance and sensitivity to DNA damage. Trends Cell Biol. 24, 268–274.

Luo, Y., Rao, M., and Zou, J. (2014). Generation of GFP reporter human induced pluripotent stem cells using AAVS1 safe harbor transcription activator-like effector nuclease. Curr. Protoc. Stem Cell Biol. 29, 5A.7.1–5A.7.18.

Ma, Y., Lin, H., and Qiu, C. (2012). High-efficiency transfection and siRNA-mediated gene knockdown in human pluripotent stem cells. Curr. Protoc. Stem Cell Biol. Chapter 2. Unit 5C.2.

Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E., and Church, G.M. (2013). RNA-guided human genome engineering via Cas9. Science 339, 823–826.

Mandal, P.K., Ferreira, L.M., Collins, R., Meissner, T.B., Boutwell, C.L., Friesen, M., Vrbanac, V., Garrison, B.S., Stortchevoi, A., Bryder, D., et al. (2014). Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 15, 643–652.

Maruyama, T., Dougan, S.K., Truttmann, M.C., Bilate, A.M., Ingram, J.R., and Ploegh, H.L. (2015). Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat. Biotechnol. 33, 538–542.

Meckler, J.F., Bhakta, M.S., Kim, M.S., Ovadia, R., Habrian, C.H., Zykovich, A., Yu, A., Lockwood, S.H., Morbitzer, R., Elsäesser, J., et al. (2013). Quantitative analysis of TALE-DNA interactions suggests polarity effects. Nucleic Acids Res. 41, 4118–4128.

Merkle, F.T., and Eggan, K. (2013). Modeling human disease with pluripotent stem cells: from genome association to function. Cell Stem Cell 12, 656–668.

Merkle, F.T., Neuhausser, W.M., Santos, D., Valen, E., Gagnon, J.A., Maas, K., Sandoe, J., Schier, A.F., and Eggan, K. (2015). Efficient CRISPR-Cas9-mediated generation of knockin human pluripotent stem cells lacking undesired mutations at the targeted locus. Cell Rep. 11, 875–883.

Miller, J.C., Tan, S., Qiao, G., Barlow, K.A., Wang, J., Xia, D.F., Meng, X., Paschon, D.E., Leung, E., Hinkley, S.J., et al. (2011). A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143–148.

Miller, J.C., Zhang, L., Xia, D.F., Campo, J.J., Ankoudinova, I.V., Guschin, D.Y., Babiarz, J.E., Meng, X., Hinkley, S.J., Lam, S.C., et al. (2015). Improved specificity of TALE-based genome editing using an expanded RVD repertoire. Nat. Methods 12, 465–471.

Miyaoka, Y., Chan, A.H., Judge, L.M., Yoo, J., Huang, M., Nguyen, T.D., Lizarraga, P.P., So, P.L., and Conklin, B.R. (2014). Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat. Methods 11, 291–293.

Montague, T.G., Cruz, J.M., Gagnon, J.A., Church, G.M., and Valen, E. (2014). CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. Nucleic Acids Res. 42, W401–W407.

Moscou, M.J., and Bogdanove, A.J. (2009). A simple cipher governs DNA recognition by TAL effectors. Science 326, 1501.

Osborn, M.J., Starker, C.G., McElroy, A.N., Webber, B.R., Riddle, M.J., Xia, L., DeFeo, A.P., Gabriel, R., Schmidt, M., von Kalle, C., et al. (2013). TALEN-based gene correction for epidermolysis bullosa. Mol. Ther. 21, 1151–1159.

Palii, S.S., Van Emburgh, B.O., Sankpal, U.T., Brown, K.D., and Robertson, K.D. (2008). DNA methylation inhibitor 5-Aza-2′-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol. Cell. Biol. 28, 752–771.

Peters, D.T., Cowan, C.A., and Musunuru, K. (2008). Genome editing in human pluripotent stem cells. In StemBook (Massachusetts General Hospital: Cambridge).

Radecke, S., Radecke, F., Cathomen, T., and Schwarz, K. (2010). Zinc-finger nuclease-induced gene repair with oligodeoxynucleotides: wanted and unwanted target locus modifications. Mol. Ther. 18, 743–753.

Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013a). Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308.

Ran, F.A., Hsu, P.D., Lin, C.Y., Gootenberg, J.S., Konermann, S., Trevino, A.E., Scott, D.A., Inoue, A., Matoba, S., Zhang, Y., and Zhang, F. (2013b). Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380–1389.

Ran, F.A., Cong, L., Yan, W.X., Scott, D.A., Gootenberg, J.S., Kriz, A.J., Zetsche, B., Shalem, O., Wu, X., Makarova, K.S., et al. (2015). In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191.

Reyon, D., Tsai, S.Q., Khayter, C., Foden, J.A., Sander, J.D., and Joung, J.K. (2012). FLASH assembly of TALENs for high-throughput genome editing. Nat. Biotechnol. 30, 460–465.

Ru, R., Yao, Y., Yu, S., Yin, B., Xu, W., Zhao, S., Qin, L., and Chen, X. (2013). Targeted genome engineering in human induced pluripotent stem cells by penetrating TALENs. Cell Regen. (Lond.) 2, 5.

Sakurai, T., Watanabe, S., Kamiyoshi, A., Sato, M., and Shindo, T. (2014). A single blastocyst assay optimized for detecting CRISPR/Cas9 system-induced indel mutations in mice. BMC Biotechnol. 14, 69.

Sander, J.D., Maeder, M.L., Reyon, D., Voytas, D.F., Joung, J.K., and Dobbs, D. (2010). ZiFiT (zinc finger targeter): an updated zinc finger engineering tool. Nucleic Acids Res. 38, W462–W468.

Sandoe, J., and Eggan, K. (2013). Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. Nat. Neurosci. 16, 780–789.

Sanjana, N.E., Cong, L., Zhou, Y., Cunniff, M.M., Feng, G., and Zhang, F. (2012). A transcription activator-like effector toolbox for genome engineering. Nat. Protoc. 7, 171–192.

Schmid-Burgk, J.L., Schmidt, T., Kaiser, V., Höning, K., and Hornung, V. (2013). A ligation-independent cloning technique for high-throughput assembly of transcription activator–like effector genes. Nat. Biotechnol. 31, 76–81.

Shalem, O., Sanjana, N.E., Hartenian, E., Shi, X., Scott, D.A., Mikkelsen, T.S., Heckl, D., Ebert, B.L., Root, D.E., Doench, J.G., and Zhang, F. (2014). Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84–87.

Silva, G., Poirot, L., Galetto, R., Smith, J., Montoya, G., Duchateau, P., and Pâques, F. (2011). Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr. Gene Ther. 11, 11–27.

Smith, C., Gore, A., Yan, W., Abalde-Atristain, L., Li, Z., He, C., Wang, Y., Brodsky, R.A., Zhang, K., Cheng, L., and Ye, Z. (2014). Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell 15, 12–13.

Stemmer, M., Thumberger, T., Del Sol Keyer, M., Wittbrodt, J., and Mateo, J.L. (2015). CCTop: an intuitive, flexible and reliable CRISPR/Cas9 target prediction tool. PLoS ONE 10, e0124633.

Sterneckert, J.L., Reinhardt, P., and Schöler, H.R. (2014). Investigating human disease using stem cell models. Nat. Rev. Genet. 15, 625–639.

Suzuki, K., Yu, C., Qu, J., Li, M., Yao, X., Yuan, T., Goebl, A., Tang, S., Ren, R., Aizawa, E., et al. (2014). Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. Cell Stem Cell 15, 31–36.

Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872.

Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S., and Jones, J.M. (1998). Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147.

Tsai, S.Q., Wyvekens, N., Khayter, C., Foden, J.A., Thapar, V., Reyon, D., Goodwin, M.J., Aryee, M.J., and Joung, J.K. (2014). Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat. Biotechnol. 32, 569–576.

Urnov, F.D., Miller, J.C., Lee, Y.L., Beausejour, C.M., Rock, J.M., Augustus, S., Jamieson, A.C., Porteus, M.H., Gregory, P.D., and Holmes, M.C. (2005). Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435, 646–651.

Valton, J., Dupuy, A., Daboussi, F., Thomas, S., Maréchal, A., Macmaster, R., Melliand, K., Juillerat, A., and Duchateau, P. (2012). Overcoming transcription activator-like effector (TALE) DNA binding domain sensitivity to cytosine methylation. J. Biol. Chem. 287, 38427–38432.

Veres, A., Gosis, B.S., Ding, Q., Collins, R., Ragavendran, A., Brand, H., Erdin, S., Cowan, C.A., Talkowski, M.E., and Musunuru, K. (2014). Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell 15, 27–30.

Vouillot, L., Thélie, A., and Pollet, N. (2015). Comparison of T7E1 and surveyor mismatch cleavage assays to detect mutations triggered by engineered nucleases. G3 (Bethesda) 5, 407–415.

Watanabe, K., Ueno, M., Kamiya, D., Nishiyama, A., Matsumura, M., Wataya, T., Takahashi, J.B., Nishikawa, S., Nishikawa, S., Muguruma, K., and Sasai, Y. (2007). A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat. Biotechnol. 25, 681–686.

Wefers, B., Panda, S.K., Ortiz, O., Brandl, C., Hensler, S., Hansen, J., Wurst, W., and Kühn, R. (2013). Generation of targeted mouse mutants by embryo microinjection of TALEN mRNA. Nat. Protoc. 8, 2355–2379.

Yang, L., Guell, M., Byrne, S., Yang, J.L., De Los Angeles, A., Mali, P., Aach, J., Kim-Kiselak, C., Briggs, A.W., Rios, X., et al. (2013). Optimization of scarless human stem cell genome editing. Nucleic Acids Res. 41, 9049–9061.

Yu, C., Liu, Y., Ma, T., Liu, K., Xu, S., Zhang, Y., Liu, H., La Russa, M., Xie, M., Ding, S., and Qi, L.S. (2015). Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell *16*, 142–147.

Zetsche, B., Gootenberg, J.S., Abudayyeh, O.O., Slaymaker, I.M., Makarova, K.S., Essletzbichler, P., Volz, S.E., Joung, J., van der Oost, J., Regev, A., et al. (2015). Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell *163*, 759–771.

Zhang, F., Cong, L., Lodato, S., Kosuri, S., Church, G.M., and Arlotta, P. (2011). Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat. Biotechnol. *29*, 149–153.

Zhang, Y., Ge, X., Yang, F., Zhang, L., Zheng, J., Tan, X., Jin, Z.B., Qu, J., and Gu, F. (2014). Comparison of non-canonical PAMs for CRISPR/Cas9-mediated DNA cleavage in human cells. Sci. Rep. *4*, 5405.

Zhang, L., Jia, R., Palange, N.J., Satheka, A.C., Togo, J., An, Y., Humphrey, M., Ban, L., Ji, Y., Jin, H., et al. (2015). Large genomic fragment deletions and insertions in mouse using CRISPR/Cas9. PLoS ONE *10*, e0120396.

Zhu, H., Lau, C.H., Goh, S.L., Liang, Q., Chen, C., Du, S., Phang, R.Z., Tay, F.C., Tan, W.K., Li, Z., et al. (2013). Baculoviral transduction facilitates TALEN-mediated targeted transgene integration and Cre/LoxP cassette exchange in human-induced pluripotent stem cells. Nucleic Acids Res. *41*, e180.

Zhu, F., Gamboa, M., Farruggio, A.P., Hippenmeyer, S., Tasic, B., Schüle, B., Chen-Tsai, Y., and Calos, M.P. (2014). DICE, an efficient system for iterative genomic editing in human pluripotent stem cells. Nucleic Acids Res. *42*, e34.

Zou, J., Maeder, M.L., Mali, P., Pruett-Miller, S.M., Thibodeau-Beganny, S., Chou, B.K., Chen, G., Ye, Z., Park, I.H., Daley, G.Q., et al. (2009). Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell *5*, 97–110.

Zuris, J.A., Thompson, D.B., Shu, Y., Guilinger, J.P., Bessen, J.L., Hu, J.H., Maeder, M.L., Joung, J.K., Chen, Z.Y., and Liu, D.R. (2015). Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. *33*, 73–80.

Zwaka, T.P., and Thomson, J.A. (2003). Homologous recombination in human embryonic stem cells. Nat. Biotechnol. *21*, 319–321.